Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrenceApril 30, 2008C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. A new report released this month by the federal Agency for Healthcare Research and Quality revealed a 200 percent increase in potentially fatal diarrheal infections in U.S. hospitals between 2000 and 2005. Additionally, the Association for Professionals in Infection Control and Epidemiology (APIC) is launching the first national prevalence study for C. diff beginning May 1. According to Patricia Raymond, MD, FACP, FACG, a Chesapeake, Virginia-based gastroenterologist, associate professor of clinical medicine at Eastern Virginia Medical School and host of the soon-to-be-launched "Your Health Choice" radio program, traditional treatment for C. diff-associated disease is the use of powerful antibiotics such as metronidazole or vancomycin, but one of the most troublesome aspects of the disease is it's high rate of recurrence. But studies show that adding the yeast-based probiotic Saccharomyces boulardii (sold under the brand name Florastor®), can cut the rate of recurrence by about half. "Almost one in four CDAD patients will experience a recurrence of symptoms after a round of antibiotic therapy alone," says Dr. Raymond. "C. difficile colitis has been in the news recently as more virulent strains are emerging. These more toxic bugs lead to higher rates of surgery for colon removal and death from the infection. Doctors are using everything in their toolboxes to combat C. difficile, and one of our proven tools is Saccharomyces boulardii. When a relapse occurs, use of Florastor during the antibiotic course can help protect against future relapses." A recent meta-analysis of 31 studies compiled and published in the American Journal of Gastroenterology concluded that S. boulardii is the only probiotic that is effective in fighting recurrent C. diff-associated disease1 Additionally, an article in the March 2006 issue of Gastroenterology and Hepatology showed that use of S. boulardii provided an almost 50 percent decrease in subsequent recurrence among patients who suffered recurrent CDAD symptoms.2 "Because Florastor (S. boulardii) is a yeast and not a bacteria, it is not killed by the strong antibiotics that are being used to kill the C. diff bacteria, so it survives in the digestive tract," says Dr. Raymond. "When the 'baby' C. diff emerge from their spores, they are greeted by a well-colonized gut, rather than an empty playground." CDAD is usually indicated by severe abdominal pain, diarrhea with mucous and blood passage, and fever. Dr. Raymond advises those exhibiting these symptoms to see a physician immediately to be tested for the presence of the C. diff toxins and to be prescribed proper antibiotics, since over-the-counter anti-diarrheal agents should be avoided. "Traditional OTC anti-diarrheal products actually slow down the speed of fluids moving through your bowels, and, in the case of C. diff, keeping the bacteria in the bowels is actually a bad thing," she adds. Healthcare practitioners are advised to adhere to strict hand-washing policies in offices and hospitals to help prevent the spread of this and other types of bacteria. Florastor has shown in more than 50 years of extensive international use to be safe and effective, with an estimated 1.7 billion daily doses sold to date. It is mentioned by the World Health Organization (WHO) for use in the management of C.diff-associated disease.3 1McFarland, L.V. (2006). Meta-analysis of probiotics for the prevention of antibiotic- associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology. 101, 812-822. 2Huebner, E.S., & Surawicz, C.M. (2006). Treatment of recurrent Clostridium difficile diarrhea. Gastroenterology and Hepatology. 2, 203-208. 3Saccharomyces boulardii: a valuable adjunct in recurrent Clostridium difficile disease" (1995) WHO Drug Information; 9;(1); 15-16. Biocodex, Inc. |
|||||||||||||||||||||
| Related Clostridium Difficile Current Events and Clostridium Difficile News Articles Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Deadly stomach infection rising in community settings, Mayo Clinic study finds Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings. Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says Healthy eating, not supplements, is the best way to keep the good bacteria in your gut healthy, says a dietitian and researcher. Structure of antibiotic ramoplanin reveals promising mechanism With the "last resort" antibiotic Vancomycin now plagued by the first signs of bacterial resistance, a scientific collaboration centered at Duke University has identified how a candidate successor antibiotic known as Ramoplanin A2 can kill pathogenic bacteria by interrupting how they form their cell membranes. Antibiotics take toll on beneficial microbes in gut It's common knowledge that a protective navy of bacteria normally floats in our intestinal tracts. Antibiotics at least temporarily disturb the normal balance. Newly discovered reactions from an old drug may lead to new antibiotics A mineral found at health food stores could be the key to developing a new line of antibiotics for bacteria that commonly cause diarrhea, tooth decay and, in some severe cases, death. Doctors identify patients at high risk of C. difficile Doctors have developed and validated a clinical prediction rule for recurrent Clostridium difficile (C. difficile) infection that was simple, reliable and accurate, and can be used to identify high-risk patients most likely to benefit from measures to prevent recurrence. Their findings appear in a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. Hospital infection control strategies for antibiotic-resistant organisms Hand-washing, a clean environment, appropriate infection barriers and early identification of patients at high risk of colonization with a transmissible microorganism remain the essential measures to prevent and control infection. What makes C-Diff superbug deadly? A major breakthrough about the potentially deadly superbug Clostridium difficile (C-diff) could lead to new ways to combat the bacterium, according to a study to be published March 1 in the journal Nature. Monash scientists debug superbug An international team of scientists, led by Monash University researchers, has uncovered the workings of a superbug that kills elderly hospital patients worldwide - a discovery that has the potential to save lives and health care systems billions of dollars each year. More Clostridium Difficile Current Events and Clostridium Difficile News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||